Rare Mutations and Fusions Patient Gateway
About rare mutations and fusions in lung cancer
Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
LATEST UPDATES
-
ILCSC Session Highlight: Histological Transformation of NSCLC into SCLC
Do you want to learn more about NSCLC transformation to SCLC? Join us for the International Lung Cancer Survivorship Conference and tune into Dr. Triparna Sen's (Icahn School of... -
ILCSC Session Highlight: Addressing Brain Mets in Lung Cancer
Leading lung cancer expert Dr. Manmeet Ahluwalia (Miami Cancer Institute) discusses brain metastases in people living with lung cancer. Register for free for the virtual... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community...
Sponsors
